BioCentury on BioBusiness,
Monday, March 9, 1998
The underlying theme in the development of FDA reform has been predictability. This is exemplified by a provision in the FDA Modernization Act of 1997 that requires FDA to provide a binding commitment, with some caveats, to approve and grant pre-specified label indications to a drug or biological product if Phase III trials achieve pre-set targets.
Taken at face value, the opportunity seems amazing, even given the scope of the reform act itself. For starters, the law requires the FDA to provide - within 45 days of a sponsor's request - an evaluation of protocols to assess whether the design is adequate to meet scientific, regulatory and labeling requirements. Such an assessment (again with caveats) can be applied to Phase III protocols that will form the primary basis for an efficacy claim.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]